Sphera Funds Management’s Fate Therapeutics FATE Stock Holding History

Sphera Funds Management’s Portfolio FATE Stock Details FATE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q2	–	Sell	-397,177	Closed	-$314K	–	115
2025 Q1	$314K	Hold	397,177	–	–	0.07%	109
2024 Q4	$655K	Buy	+397,177	New	+$1M	0.12%	99
2022 Q2	–	Sell	-89,425	Closed	-$3.47M	–	65
2022 Q1	$3.47M	Sell	89,425 -96,051	-52%	-$3.72M	0.49%	45
2021 Q4	$10.9M	Sell	185,476 -33,823	-15%	-$1.92M	1.19%	27
2021 Q3	$13M	Buy	219,299 +54,000	+33%	+$4.24M	1.09%	21
2021 Q2	$14.3M	Buy	165,299 +55,492	+51%	+$4.47M	0.97%	27
2021 Q1	$9.05M	Buy	109,807 +27,807	+34%	+$2.66M	0.69%	34
2020 Q4	$7.46M	Sell	82,000 -106,000	-56%	-$6.58M	0.66%	49
2020 Q3	$7.51M	Sell	188,000 -37,000	-16%	-$1.29M	0.74%	40
2020 Q2	$7.72M	Buy	+225,000	New	+$6.71M	0.73%	36

Other funds holding FATE

Redmile Group San Francisco, California $1.49B AUM 208.7% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return

Johnson & Johnson New Brunswick, New Jersey $799M AUM 253.51% 1-Year Est. Return

VPC

Vestal Point Capital New York $4.28B AUM 239% 1-Year Est. Return

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return

Sphera Funds Management's FATE Position: Q2 2025 in Review

Sphera Funds Management sold out of Fate Therapeutics (FATE) in Q2 2025, closing a stake of 397,177 shares — an estimated $314K sold.

Sphera Funds Management first reported a position in FATE in Q2 2020 and held it in 10 quarters. The position peaked at $14.3M in Q2 2021. 139 funds tracked by Wall St. Rank hold FATE as of Q2 2025.

Sphera Funds Management reported no remaining Fate Therapeutics position as of Q2 2025 after selling out during the quarter.
Sphera Funds Management sold 397,177 Fate Therapeutics shares in Q2 2025, an estimated $314K.
Sphera Funds Management first reported a position in Fate Therapeutics in Q2 2020 and held it in 10 quarters.
Sphera Funds Management's Fate Therapeutics position peaked at $14.3M in Q2 2021.
139 funds tracked by Wall St. Rank held Fate Therapeutics as of Q2 2025.

Based on Sphera Funds Management's 13F filing for Q2 2025, filed 14 Aug 2025.